MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcript
MiNK Therapeutics Q1 Earnings Call Highlights
MiNK Therapeutics NASDAQ: INKT said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management said support at least 12 months of operating runway.
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. ( INKT ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Stefanie Perna-Nacar Jennifer Buell - President, CEO & Director Terese Hammond - Head of Inflammatory & Pulmonary Diseases Christine Klaskin - Treasurer and Principal Financial & Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Mayank Mamtani - B.
MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Christine M. Klaskin - Treasurer and Principal Financial & Accounting Officer Jennifer S.
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Zack Armen - IR Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Thiago Favano - Senior Director, Portfolio Operations Conference Call Participants Emily Bodnar - H.C. Wainwright Matt Phipps - William Blair Operator Thank you for standing by.
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Alexa Buffa - Corporate Communications Jennifer Buell - President and Chief Executive Officer Christine Klaskin - Principal Financial and Accounting Officer Paul Ibbett - Scientist Conference Call Participants Emily Bodnar - H.C. Wainwright Operator Thank you for standing by.
MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Jennifer Buell - President and Chief Executive Officer Marc Van Dijk - Chief Scientific Officer Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Jack Allen - Baird Mayank Mamtani - B.
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
MiNK Therapeutics, Inc. (INKT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
